89bio’s FGF21 Analog May Offer Fibrosis Benefit In Cirrhotic NASH Patients

At AASLD, 89bio presented subgroup analysis from its successful Phase IIb NASH study indicating that the drug may meaningfully reduce fibrosis even in the sickest patients, those with cirrhosis.